Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. The findings do not support CBD as an effective treatment for fibromyalgia pain based on current evidence. Clinicians should communicate realistic expectations to patients who are considering CBD for this condition.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized, double-blind, placebo-controlled trial provides the rigorous evidence needed to evaluate CBD’s analgesic efficacy in fibromyalgia, a condition for which current pharmacotherapy has limited effectiveness and significant adverse effects. The findings establish a necessary evidentiary foundation for clinical decision-making regarding CBD use in fibromyalgia management and help determine whether this agent warrants consideration as an alternative or adjunctive treatment option. Given widespread off-label CBD use in fibromyalgia patients despite limited efficacy data, this study addresses a critical gap between clinical practice and evidence-based medicine.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
? This Danish randomized controlled trial adds meaningful data to the fibromyalgia-CBD evidence base, though several factors warrant cautious interpretation before implementation. Single-center studies have inherent limitations in generalizability, and fibromyalgia’s heterogeneous presentation means results may not apply uniformly across all patient phenotypes; additionally, the trial’s methodology appears incomplete in the provided abstract, making it difficult to assess for potential biases in outcome measurement or follow-up duration. The growing clinical use of CBD for fibromyalgia pain often outpaces rigorous evidence, so this study’s contribution to either supporting or refuting efficacy claims will meaningfully influence counseling conversations with patients already using or considering CBD. For practitioners, the key implication is that while this trial may help refine our understanding of CBD’s role in fibromyalgia management, individual patient response remains variable and decisions should incorporate baseline symptom severity, comorbidities, concurrent medications, and realistic outcome expectations rather than relying on any single study.
|
Have thoughts on this? Share it:
